Brief: Algernon Pharmaceuticals Engages Maxim Group To Explore Spin-Off Of Ifenprodil Phase 2 Chronic Cough Drug Development Program
27/06/2023 13:12
June 27 (Reuters) - Algernon Pharmaceuticals Inc
AGN.CD :
* ALGERNON PHARMACEUTICALS ENGAGES MAXIM GROUP TO EXPLORE
SPIN-OFF
OF ITS IFENPRODIL PHASE 2 CHRONIC COUGH DRUG DEVELOPMENT PROGRAM
Source text for Eikon: ID:nGNX1m5PJM
Further company coverage: AGN.CD
((reuters.briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement